A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer - Takeaways - MDSpire

A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer

  • By

  • Boyu Chen

  • Jing Liu

  • Kexin Gan

  • Liqun Yang

  • Peng Qiu

  • Boqing Ma

  • Wen Chen

  • July 10, 2026

  • 0 min

Share

  • 1

    A network meta-analysis assessed endocrine adverse events associated with immune checkpoint inhibitors in colorectal cancer.

  • 2

    Six randomized controlled trials were included, focusing on the comparative risk of endocrine toxicities across ICI regimens.

  • 3

    ICI-based regimens were linked to a higher burden of thyroid-related toxicity compared to conventional therapies.

  • 4

    Pembrolizumab and ICI combined with tyrosine kinase inhibitors significantly increased the risk of hypothyroidism.

  • 5

    The findings highlight the need for proactive endocrine monitoring and standardized management in patients receiving ICIs.

Original Source(s)

A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer

  • by Boyu Chen, Jing Liu, Kexin Gan, Liqun Yang, Peng Qiu, Boqing Ma, Wen Chen

  • July 10, 2026

Related Content

Analysis of clinicopathological features and prognosis of mesenteric versus anti-mesenteric rectal cancer: a single-center retrospective cohort study

Case Report: Thoracic SMARCA4-deficient undifferentiated tumor with extraocular muscle metastasis: a rare case hidden in diplopia

Long non-coding RNAs and their potential role in predicting immunotherapy response and prognosis: a systematic review